CN1479630A - 诱导癌细胞死亡和肿瘤消退的方法 - Google Patents

诱导癌细胞死亡和肿瘤消退的方法 Download PDF

Info

Publication number
CN1479630A
CN1479630A CNA018201032A CN01820103A CN1479630A CN 1479630 A CN1479630 A CN 1479630A CN A018201032 A CNA018201032 A CN A018201032A CN 01820103 A CN01820103 A CN 01820103A CN 1479630 A CN1479630 A CN 1479630A
Authority
CN
China
Prior art keywords
inhibitor
cancer
alkyl
ras
fpt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA018201032A
Other languages
English (en)
Chinese (zh)
Inventor
Q
乔治Q·戴利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CN1479630A publication Critical patent/CN1479630A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CNA018201032A 2000-10-05 2001-10-05 诱导癌细胞死亡和肿瘤消退的方法 Pending CN1479630A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23824000P 2000-10-05 2000-10-05
US60/238,240 2000-10-05

Publications (1)

Publication Number Publication Date
CN1479630A true CN1479630A (zh) 2004-03-03

Family

ID=22897049

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA018201032A Pending CN1479630A (zh) 2000-10-05 2001-10-05 诱导癌细胞死亡和肿瘤消退的方法

Country Status (14)

Country Link
US (1) US6777415B2 (https=)
EP (1) EP1322334A2 (https=)
JP (1) JP2004510733A (https=)
CN (1) CN1479630A (https=)
AU (2) AU1186202A (https=)
BR (1) BR0114430A (https=)
CA (1) CA2424797C (https=)
HK (1) HK1052870A1 (https=)
HU (1) HUP0302913A3 (https=)
MX (1) MXPA03003011A (https=)
NO (1) NO20031531L (https=)
NZ (1) NZ524936A (https=)
WO (1) WO2002028381A2 (https=)
ZA (1) ZA200302523B (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102274513A (zh) * 2011-07-06 2011-12-14 南开大学 ERK1/2抑制剂通过刺激巨噬细胞干扰素γ表达抑制肿瘤生长
CN102626416A (zh) * 2012-05-11 2012-08-08 江苏省人民医院 他莫昔芬联合雷帕霉素、人参皂苷Rg3复合物在制备治疗肝癌药物中的应用

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6369138B2 (en) 1997-07-11 2002-04-09 Bridgestone Corporation Processability of silica-filled rubber stocks with reduced hysteresis
WO2008109417A1 (en) * 2007-03-02 2008-09-12 Case Western Reserve University Mgmt inhibitor combinations for the treatment of neoplastic disorders
US20020077301A1 (en) * 2000-10-05 2002-06-20 Whitehead Institute For Biomedical Research Effects of combined administration of farnesyl transferase inhibitors and signal transduction inhibitors
US20040126755A1 (en) * 2001-08-29 2004-07-01 Stephan Dietrich A Gene expression based method for distinguishing metastatic from non-metastatic forms of a tumor, and use in designing therapeutic drugs
WO2003047697A2 (en) * 2001-11-30 2003-06-12 Schering Corporation Use of an farsenyl protein tranferase inhibitor in combination with other antineoplastic agents for the manufacture of a medicament against cancer
AU2002346644A1 (en) * 2001-12-03 2003-06-17 Schering Corporation Use of fpt inhibitors and at least two antineoplastic agents in the treatment of cancer
US20050004008A1 (en) * 2002-03-01 2005-01-06 Frackelton A. Raymond SHC proteins as therapeutic targets in proliferative diseases
CA2477953A1 (en) * 2002-03-01 2003-09-12 Roger Williams Hospital Shc protein-related methods and compositions for the prognosis of breast, prostate and ovarian cancer
US20050101576A1 (en) * 2003-11-06 2005-05-12 Novacea, Inc. Methods of using vitamin D compounds in the treatment of myelodysplastic syndromes
US7691905B2 (en) * 2002-12-24 2010-04-06 New York University Inhibition of melanogenesis and melanoma metastasis with p-aminobenzoic acid (PABA)
JP2007510661A (ja) * 2003-11-06 2007-04-26 シェーリング　コーポレイション 乳癌の治療のための、ファルネシルトランスフェラーゼインヒビターと抗ホルモン剤との組合せ
US20060205810A1 (en) * 2004-11-24 2006-09-14 Schering Corporation Platinum therapeutic combinations
US20070148660A1 (en) * 2005-06-16 2007-06-28 The Regents Of The University Of California Treatment of maladaptive substance use with H-ras antagonists
US20080255171A1 (en) * 2005-10-07 2008-10-16 Manley Paul W Combination of Nilotinib with Farnesyl Transferase Inhibitors
JP2009516167A (ja) * 2005-11-11 2009-04-16 ロジャー・ウィリアムズ・ホスピタル 癌処置における予測マーカーとしてのｐ６６−ｓｈｃ

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69120430D1 (de) 1990-12-18 1996-07-25 Wellcome Found Mittel zur verstaerkung der wirkung von antitumoralen mittel und zur widerstandsbekaempfung von vielfachdrogen
US5874442A (en) 1995-12-22 1999-02-23 Schering-Plough Corporation Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease
CA2250232A1 (en) 1996-04-03 1997-10-09 Allen I. Oliff A method of treating cancer
JP2000508335A (ja) * 1996-05-30 2000-07-04 メルク エンド カンパニー インコーポレーテッド 癌の治療方法
IL133389A0 (en) 1997-06-17 2001-04-30 Schering Corp Novel n-substituted urea inhibitors of farnesyl-protein transferase
JP2002510308A (ja) 1997-06-17 2002-04-02 シェーリング コーポレイション ファルネシルタンパク質トランスフェラーゼインヒビターとしてのベンゾ（５，６）シクロヘプタ（１，２−ｂ）ピリジン誘導体
US6096757A (en) 1998-12-21 2000-08-01 Schering Corporation Method for treating proliferative diseases
DK1140938T3 (da) 1999-01-11 2003-12-22 Univ Princeton Højaffinitetsinhibitorer for målvalidering og anvendelser heraf
US6316462B1 (en) 1999-04-09 2001-11-13 Schering Corporation Methods of inducing cancer cell death and tumor regression
US6664288B1 (en) * 1999-04-14 2003-12-16 Dana Farber Cancer Institute, Inc. Method and composition for the treatment of cancer
US6465448B1 (en) * 1999-08-13 2002-10-15 Case Western Reserve University Methoxyamine potentiation of temozolomide anti-cancer activity
AU2001294511A1 (en) * 2000-06-30 2002-01-08 The Regents Of The University Of California New strategy for leukemia therapy
US20020077301A1 (en) * 2000-10-05 2002-06-20 Whitehead Institute For Biomedical Research Effects of combined administration of farnesyl transferase inhibitors and signal transduction inhibitors

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102274513A (zh) * 2011-07-06 2011-12-14 南开大学 ERK1/2抑制剂通过刺激巨噬细胞干扰素γ表达抑制肿瘤生长
CN102626416A (zh) * 2012-05-11 2012-08-08 江苏省人民医院 他莫昔芬联合雷帕霉素、人参皂苷Rg3复合物在制备治疗肝癌药物中的应用

Also Published As

Publication number Publication date
WO2002028381A3 (en) 2003-03-27
AU2002211862B2 (en) 2007-03-15
HUP0302913A3 (en) 2005-05-30
WO2002028381A2 (en) 2002-04-11
NO20031531L (no) 2003-06-05
US20020128280A1 (en) 2002-09-12
MXPA03003011A (es) 2003-07-14
BR0114430A (pt) 2004-01-06
HK1052870A1 (zh) 2003-10-03
NO20031531D0 (no) 2003-04-04
NZ524936A (en) 2005-08-26
CA2424797A1 (en) 2002-04-11
ZA200302523B (en) 2004-08-24
US6777415B2 (en) 2004-08-17
JP2004510733A (ja) 2004-04-08
HUP0302913A2 (hu) 2003-12-29
EP1322334A2 (en) 2003-07-02
CA2424797C (en) 2009-12-29
AU1186202A (en) 2002-04-15

Similar Documents

Publication Publication Date Title
CN1479630A (zh) 诱导癌细胞死亡和肿瘤消退的方法
US12569542B2 (en) Treatment of cancer with immune stimulators
AU783177B2 (en) Methods of inducing cancer cell death and tumor regression
TW202317124A (zh) Erk1/2及shp2抑制劑之組合療法
CA3065365C (en) USE OF 1-[4-BROMO-5-[1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDINE-3-YL]-2-FLUOROPHENYL]-3-PHENYLUREA AND ITS ANALOGUES FOR THE TREATMENT OF CANCERS ASSOCIATED WITH GENETIC ABNORMALITIES IN THE PLATELET-DERIVED GROWTH FACTOR ALPHA RECEPTOR
US20240285625A1 (en) Erk1/2 and kras g12c inhibitors combination therapy
KR20190033526A (ko) 병용 요법
AU2002211862A1 (en) Methods of inducing cancer cell death and tumor regression
D’Cruz et al. Novel Bruton’s tyrosine kinase inhibitors currently in development
HK1251165A1 (en) Treatment method combining mdm2 inhibitor and btk inhibitor
TW202320792A (zh) 包含ｆｇｆｒ抑制劑及ｋｒａｓ抑制劑之組合療法
AU2007272330A1 (en) Interleukin 21 and tyrosine kinase inhibitor combination therapy
CN1259868A (zh) 法尼基转移酶抑制剂与HMG CoA还原酶抑制剂结合用于治疗癌症
EP3999065B1 (en) Therapeutic compositions comprising idelalisib and defactinib for treating breast cancers
JP2024523861A (ja) がんを処置するための併用療法におけるｅｇｆｒ阻害剤およびｐｅｒｋ活性化剤、ならびにこれらの使用
CN120682121A (zh) 一种含三氟甲基萘基脲的化合物及在抗肿瘤中的应用
WO2022271939A1 (en) Erk1/2 and cdk4/6 inhibitors combination therapy
WO2025245045A1 (en) Methods of treating lung cancer
CA3222730A1 (en) Erk1/2 and egfr inhibitors combination therapy
JP2007507552A (ja) Ｉｇｆ１ｒ阻害剤が誘発する高血糖を治療する方法
Eckhardt Novel Agents in Anticancer Drug Therapy I (Antiangiogenic Agents, Egfr Inhibitors)
HK40006485A (en) Combination therapies
AU2005248948A1 (en) Methods of inducing cancer cell death and tumor regression
HK1228375B (en) N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of shp2

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication